HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kratom Supplement Marketers Dispute FDA Warning, Ask For Review

This article was originally published in The Rose Sheet

Executive Summary

In addition to a review of the advisory announced by FDA Commissioner Gottlieb, a trade group petitions the agency for a meeting to allow stakeholders "to correct misstatements and factual errors on the science regarding the safety and addiction potential of kratom."

You may also be interested in...



Drug Abuse Withdrawal Supplement Marketers Warned, Claims And Sales Continue

FDA and FTC send joint warning letters to 11 US firms about 12 products marketed as unapproved drugs with claims about aiding in the treatment of opioid addiction and withdrawal. FDA also thanks CSPI for suggesting the agencies investigate a scourge of fraudulent drug-abuse withdrawal claims.

Opioid-Withdrawal 'Aids' Warrant Immediate FDA, FTC Action – CSPI

FDA and the Federal Trade Commission should bring immediate enforcement action against marketers of non-kratom dietary supplements promoted as opioid-withdrawal aids, says the Center for Science in the Public Interest in letters to the agency and commission Dec. 8. The nonprofit identified eight supplement products making opioid-withdrawal claims without sufficient science to support the statements.

Kratom Experts Seek NIDA As Ally To Show Herb's Safety And Benefits

American Kratom Association representatives also this week are lobbying state and local officials in Georgia to withdraw their findings linking 17 deaths directly to the use of kratom, and testifying at a Utah state legislative panel hearing on alternative pain remedies.

Related Content

Topics

UsernamePublicRestriction

Register

RS121321

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel